UCB Announces $2B U.S. Biologics Plant in Georgia — Domestic Manufacturing Bet Pays Political Dividends
By FieldPulse Editorial · March 24, 2026
Tags: Policy, Pipeline
UCB will build its first major U.S. biologics manufacturing facility in Georgia, a $2 billion investment that positions the Belgian pharma company ahead of growing political pressure to onshore pharmaceutical production.
UCB announced Monday it will invest $2 billion to build a large-scale biologics manufacturing facility in Georgia, its first major domestic production site in the United States.
The plant will be located near UCB's U.S.
headquarters in the Atlanta area, deepening the company's footprint in a region that has become an increasingly significant hub for life sciences operations in the American Southeast.
The announcement arrives at a moment when domestic pharmaceutical manufacturing has become a live political issue in Washington.
Pressure from the current administration — and from both sides of the aisle in Congress — to reduce U.S.
dependence on foreign-manufactured biologics has been building for several years, accelerated by supply chain disruptions that exposed vulnerabilities in the global pharmaceutical production network.
For UCB, a Belgian company with deep roots in neurology and immunology, the Georgia investment serves multiple purposes.
It addresses political and regulatory risk in a market that generates a substantial share of the company's global revenue.
It also positions UCB favorably as policymakers increasingly scrutinize where drugs sold in the U.S.
are actually made — a calculation that may grow more consequential if legislative incentives or procurement preferences for domestically produced drugs gain traction.
Biologics manufacturing is capital-intensive and technically demanding, which is part of why the sector has historically been concentrated in a relatively small number of specialized facilities globally.
A $2 billion greenfield investment is not a decision taken lightly, and it signals UCB's long-term confidence in its U.S.
business and pipeline.
For pharma sales reps working in markets where UCB competes — including epilepsy, Crohn's disease, psoriasis, and other immunology indications — the manufacturing news is relevant context for customer conversations.
Physicians and health system procurement teams are increasingly aware of supply chain.
Source: https://www.fiercepharma.com/